Brief: AC Immune Initiates Phase 1 Clinical Trial Of NLRP3 Inhibitor
24/02/2026 12:16
Feb 24 (Reuters) - AC Immune SA ACIU.O: AC IMMUNE INITIATES PHASE 1 CLINICAL TRIAL OF NLRP3 INHIBITOR AC IMMUNE SA - PHASE 1 RESULTS EXPECTED IN H2 2026 Source text: ID:nGNXvWxwr Further company coverage: ACIU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture